Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

A Phase II Open-label Pilot Study Evaluating the Maintenance Therapy With Exemestane Plus Everolimus After Induction Chemotherapy in Patients With Hormone-receptor Positive Metastatic Breast Cancer

The purpose of this study is to determine whether exemestane plus everolimus are effective in the treatment of patients who have achieved disease stabilization after induction chemotherapy for hormone-receptor positive metastatic breast cancer.

Study Overview

• Status: Unknown
• Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast
• Intervention / Treatment: Drug: Exemestane; Drug: Everolimus

Detailed Description

Postmenopausal women with HR-positive, HER2-negative metastatic breast cancer achieving clinical benefit after the induction chemotherapy for visceral disease with sign(s) and/or symptom(s) will be recruited to receive study the maintenance treatment of everolimus plus exemestane.

• Study Type: Interventional
• Enrollment (Anticipated): 35
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Hong Kong, China
    • UNIMED Medical Institute
    • Contact: Louis Chow; Phone Number: (852)28610286
    • Principal Investigator: Louis Chow

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Postmenopausal women as defined in the protocol page 9;
• Histologically and/or cytologically confirmed invasive breast cancer with stage IV disease according to AJCC;
• Confirmed ER/PR-positive, and HER-2 negative tumor;
• Disease progression on or following prior endocrine therapy with tamoxifen or non-steroidal aromatase inhibitor, as defined in protocol, prior to standard of care (SOC) induction chemotherapy
• Patient with documented evidence of visceral disease (including but not limited to hepatic involvement and pulmonary lymphangitic spread of tumor) with sign(s) and/or symptom(s) prior to SOC induction chemotherapy should achieve disease stabilization after the SOC induction chemotherapy, confirmed upon 2 consecutive routine tumor assessments;
• ECOG performance status ≤ 2 or Karnofsky performance status ≥ 50% prior to the start of study treatment;
• Adequate organ function prior to the start of study treatment as defined in the protocol;
• Able to swallow and retain oral medication;
• Able to give written informed consent;

Exclusion Criteria:

• Male patient;
• Metastatic disease limited to the bone or soft tissues only and with no history of other visceral metastases;
• History of brain or other CNS metastases;
• Previous treatment with exemestane, unless exemestane was administered in the adjuvant setting and stopped >1 year before metastatic relapse;
• Untreated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC - or - treated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC without clinical benefit;
• History of neurological or psychiatric disorders;
• Any serious cardiovascular diseases in the previous 6 months;
• Impairment of gastrointestinal function or gastrointestinal disease;
• Patients with uncontrolled infection;
• Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin defined as 1 mg a day);
• Chronic treatment with systemic steroids or another immunosuppressive agent;
• Patients with a pre-existing peripheral neuropathy > grade 1;
• Patients who are hepatitis B and/or hepatitis C carriers;
• Known human immunodeficiency virus infection;
• Prior exposure to mTOR inhibitors;
• Hypersensitivity to rapamycin or other similar compounds;
• Patients taking medications known to be inhibitors or inducers of CYP3A4 and/or PgP will not be included in this study;
• Prior treatment with any investigational agent within the preceding 4 weeks;
• Other conditions in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Other protocol-defined inclusion/exclusion criteria may apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Exemestane plus Everolimus; Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity	Drug: Exemestane; Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.; Other Names: Aromasin; Drug: Everolimus; Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.; Other Names: Afinitor, RAD001

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival	defined as from date of treatment initiation with everolimus plus exemestane to the date of progression or death if no documented disease progression	Every 8 weeks in the first 24 weeks of treatment and every 12 weeks thereafter, up to 8 months (estimated)

Secondary Outcome Measures

Outcome Measure	Time Frame
Response rate	Every 8 weeks, up to 8 months (estimated)
Clinical benefit rate	Every 8 weeks, up to 8 months (estimated)
Overall survival	date of treatment initiation with everolimus plus exemestane until the date of death, censored at the last date known alive, whichever came first, assessed up to 32 months
Incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs)	Continuous during the study, up to 28 days after the last treatment

Collaborators and Investigators

• Sponsor: Organisation for Oncology and Translational Research
• Investigators: Principal Investigator: Louis Chow, Organisation for Oncology and Translational Research

Study record dates

Study Major Dates

• Primary Completion (ANTICIPATED): August 1, 2016

Study Registration Dates

• First Submitted: December 16, 2013
• First Submitted That Met QC Criteria: December 29, 2013
• First Posted (ESTIMATE): January 1, 2014

Study Record Updates

• Last Update Posted (ESTIMATE): January 1, 2014
• Last Update Submitted That Met QC Criteria: December 29, 2013
• Last Verified: December 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms by Site; Breast Diseases; Neoplasms; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Hormones, Hormone Substitutes, and Hormone Antagonists; Hormone Antagonists; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Everolimus; Exemestane
• Other Study ID Numbers: M004/EXE-EVE